allogeneic– tag –
-
Japan Launches Akougo (Vandefitemcel): A Groundbreaking Cell Therapy Revolutionizing Chronic Motor Impairment Post-TBI
Reddit (引用元: 日刊工業新聞) Japan Overview SanBio has introduced Akougo (Vandefitemcel) in Japan, a pioneering cell therapy designed to address chronic motor impairment following traumatic brain injury (TBI). This innovative regenerati... -
European Biotechs Lead Next-Gen Cell & Gene Therapy Manufacturing Innovation: From Scalable Stem Cells to Clinical CAR Treg Trials
PharmTech ヨーロッパ Overview European biotech companies are pioneering next-generation manufacturing technologies crucial for the commercial viability and accessibility of cell and gene therapies (CGTs), prioritizing scalable allogeneic... -
Fate Therapeutics’ iPSC-Derived CAR-T FT836 Shows Early Phase 1 Data Suggesting Colorectal Tumor Shrinkage with Nine Engineered Edits
CRISPR Medicine News USA Overview Fate Therapeutics has announced initial Phase 1 data for FT836, an iPSC-derived, off-the-shelf CAR-T cell therapy. In a trial involving nine colorectal cancer patients, reductions in target lesion size a... -
CRISPR Medicine News Roundup: Sickle Cell CRISPR Drug Shows Potent Results in Young Children, Caribou’s Off-the-Shelf CAR-T Delivers Positive Phase 1 Data
CRISPR Medicine News USA Overview A CRISPR Medicine News summary article reports that the first approved CRISPR gene therapy for sickle cell disease demonstrated equally potent results in children as young as 5 years old. Additionally, C... -
Genomic Engineering Strategies and Alternative Cell Types in Allogeneic T-Cell Immunotherapy Platforms Enable Scalable Cancer Treatment
Academic Publication Global Overview Allogeneic T-cell therapy is emerging as a highly promising strategy in cancer immunotherapy due to its scalability and 'off-the-shelf' availability, overcoming logistical and manufacturing constraint... -
Allogeneic CAR-T Cell Therapies Promise to Overcome Autologous Challenges and Expand Therapeutic Potential in Solid Tumors
PubMed (Review Article) Global Overview This review article details how allogeneic CAR-T cell therapies demonstrate clinical benefits in B-cell malignancies and offer the potential to overcome key limitations of autologous CAR-T, such as... -
Nkarta Develops Off-the-Shelf NK Cell Therapies NKX019 and NKX101 for Solid and Hematologic Malignancies, Balancing Scalability with Clinical Efficacy
Umbrex USA Overview Nkarta, a clinical-stage biotechnology company, specializes in off-the-shelf NK cell therapies derived from healthy donors, developing NKX019 for B-cell malignancies and NKX101 for Acute Myeloid Leukemia (AML) as its ... -
Engineered Allogeneic Treg Cell Therapy TRX103 Enters Phase 1/2a Clinical Trials for Crohn’s Disease and GvHD Prevention
Frontiers Global Overview The gene-edited allogeneic Treg cell therapy candidate TRX103, designed as a scalable, off-the-shelf application, has commenced Phase 1/2a clinical evaluation for Crohn's disease and Graft-versus-Host Disease (G... -
Cell Therapy Startups Like Orca Bio and Allogene Lead Cancer & Autoimmune Disease Treatment with Off-the-Shelf Platforms
New Market Pitch USA Overview Cell therapy startups such as Orca Bio and Allogene, utilizing off-the-shelf platforms, are spearheading advancements in allogeneic and iPSC-derived therapies for cancer and autoimmune diseases. Key differen... -
EU NK Cell Market Projected for Twofold Growth by 2035, Driven by Increasing Allogeneic NK Cell Therapy Approvals
IndexBox USA Overview This article outlines a report from IndexBox on the European Union's NK cell market, which is expected to double in size between 2026 and 2035. This growth is primarily driven by the approval and commercial launch o...
